I called them about their decision to stop using Omontys and haven't heard from them either.
Maybe if I make it a shareholder query I'll get some kind of response.
Besides whether or not affy had received communications as to that decision on Feb.22 it would also be nice to know whether Takeda actually did any dna testing with Fresenius and the FDA that we heard about last summer and if Takeda interviewed any Fresenius employees.
According to Lisa at affy the shareholder suit settlement isn't final and might not be until Dec.
For those shareholders interested I thought the timing of the releases from Affy mgt is very important.
Lisa mentioned the Feb 14 letter release was inadvertent. What does that mean. Did someone trade on the info making it necessary to make it public before an insider trade was discovered? Who in the company would have access to it and inadvertently released it? Legal? Or maybe the receptionist read it over the intercom.
I don't know how is it possible for any pharma to file an NDA and then go for approval, encounter some issues and then without doing further investigation of the root cause, just saying, "I;m withdrawing the Drug?"
I don't know how FDA reacts to it? Will they simply say "Go ahead and withdraw? or will FDA ask for more explanation?